According to a media release issued earlier today, Takeda Pharmaceuticals and it’s wholly owned subsidiary, Millennium, are starting the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer.
TAK-700 is a nonsteroidal androgen synthesis inhibitor. In preclinical studies it has been shown to selectively bind to and inhibit the enzyme 17,20-lyase in both the testes and adrenal glands, and thereby to suppress the production of androgens.
The open-label, multiple-dose study will examine the safety and effectiveness of TAK-700 in patients with chemotherapy-naïve, metastatic, castration-resistant prostate cancer. Primary endpoints of the study are safety and tolerability with secondary measures that include efficacy, pharmacokinetic, and pharmacodynamic endpoints.
Filed under: Drugs in development Tagged: | castration-resistant prostate cancer, CRPC, TAK-700
Search for new and
ongoing trials on the
CTAG PCa web site
